Non-alcoholic Steatohepatitis Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, II, III, IV), By Study Design (Interventional, Expanded Access), By Region (APAC, Europe), And Segment Forecasts, 2022 - 2030

Table of Contents

Chapter 1 Methodology and Scope
                  1.1 Market Segmentation & Scope
                      1.1.1 Estimates and forecast timeline
                  1.2 Research Methodology
                  1.3 Information Procurement
                      1.3.1 Purchased database
                      1.3.2 GVR’s internal database
                      1.3.3 Secondary sources
                      1.3.4 Primary research
                      1.3.5 Details of primary research
                  1.4 Information or Data Analysis
                      1.4.1 Data analysis models
                  1.5 Market Formulation & Validation
                  1.6 Region Wise Market Calculation
                      1.6.1 Region Wise Market: Base Estimates
                      1.6.2 Global Market: CAGR Calculation
                  1.7 List of Secondary Sources
                  1.8 Objectives
                      1.8.1 Objective - 1: Understanding market dynamics
                      1.8.2 Objective - 2: Understanding market estimates and forecasts
                      1.8.3 Objective - 3: Understanding attributes such as strategy framework and competitor categorization
                      1.8.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size.
Chapter 2 Executive Summary
                  2.1 Market Outlook
Chapter 3 Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market: Variables, Trends, & Scope
                  3.1 Market Segmentation and Scope
                  3.2 Market Dynamics
                      3.2.1 Market Driver Analysis
                          3.2.1.1 Increasing pharmaceutical R&D investment
                          3.2.1.2 Rising diabetic population & Obesity
                          3.2.1.3 Rising Healthcare expenditure
                      3.2.2 Market Restraint Analysis
                          3.2.2.1 Lack of Awareness
                          3.2.2.2 Barriers to enrollment
                          3.2.2.3 Lethargic drug approval process
                  3.3 Penetration & Growth Prospect Mapping
                  3.4 COVID-19 Impact on the Market
                  3.5 Major Deals and Strategic Alliances Analysis
                  3.6 NASH Clinical Trials: Market Analysis Tools
                      3.6.1 Industry Analysis - Porter’s
                      3.6.3 PESTEL Analysis
Chapter 4 Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market: Phase Segment Analysis
                  4.1 Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market: Phase Market Share Analysis, 2021 & 2030
                  4.2 Phase I
                      4.2.1 Phase I Market, 2018 - 2030 (USD Million)
                  4.3 Phase II
                      4.3.1 Phase II Market, 2018 - 2030 (USD Million)
                  4.4 Phase III
                      4.4.1 Phase III Market, 2018 - 2030 (USD Million)
                  4.5 Phase IV
                      4.5.1 Phase IV, 2018 - 2030 (USD Million)
Chapter 5 Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market: Study Design Segment Analysis
                  5.1 Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market: Study Design Market Share Analysis, 2021 & 2030
                  5.2 Interventional
                      5.2.1 Interventional Non-alcoholic Steatohepatitis (NASH) Clinical Trials market, 2018 - 2030 (USD Million)
                  5.3 Observational
                      5.3.1 Observational Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                  5.4 Expanded Access
                      5.4.1 Expanded Access Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
Chapter 6 Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market: Regional Analysis
                  6.1 Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market: Regional Market Share Analysis, 2020 & 2028
                  6.2 North America
                      6.2.1 North America Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.2.2 U.S.
                          6.2.2.1 U.S. Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.2.3 Canada
                          6.2.3.1 Canada Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                  6.3 Europe
                      6.3.1 Europe Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.3.2 U.K.
                          6.3.2.1 U.K. Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.3.3 Germany
                          6.3.3.1 Germany Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.3.4 France
                          6.3.4.1 France Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.3.5 Italy
                          6.3.5.1 Italy Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.3.6 Spain
                          6.3.6.1 Spain Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                  6.4 Asia Pacific
                      6.4.1 Asia Pacific Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.4.2 Japan
                          6.4.2.1 Japan Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.4.3 China
                          6.4.3.1 China Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.4.4 India
                          6.4.4.1 India Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.4.5 Australia
                          6.4.5.1 Australia Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.4.6 South Korea
                          6.4.6.1 South Korea Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                  6.5 Latin America
                      6.5.1 Latin America Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.5.2 Brazil
                          6.5.2.1 Brazil Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.5.3 Mexico
                          6.5.3.1 Mexico Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.5.4 Argentina
                          6.5.4.1 Argentina Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.5.5 Colombia
                          6.5.5.1 Colombia Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                  6.6 MEA
                      6.6.1 MEA Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.6.2 South Africa
                          6.6.2.1 South Africa Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.6.3 Saudi Arabia
                          6.6.3.1 Saudi Arabia Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
                      6.6.4 UAE
                          6.6.4.1 UAE Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, 2018 - 2030 (USD Million)
Chapter 7 Company Profiles
                  7.1 Pfizer Inc
                      7.1.1 Company Overview
                      7.1.2 Financial Performance
                      7.1.3 Service Benchmarking
                      7.1.4Strategic Initiatives
                  7.2 Shire Plc
                      7.2.1 Company Overview
                      7.2.2 Financial Performance
                      7.2.3 Service Benchmarking
                      7.2.4Strategic Initiatives
                  7.3 Novartis AG
                      7.3.1 Company Overview
                      7.3.2 Financial Performance
                      7.3.3 Service Benchmarking
                      7.3.4 Strategic Initiatives
                  7.4 Icon Plc.
                      7.4.1 Company Overview
                      7.4.2 Financial Performance
                      7.4.3 Service Benchmarking
                      7.4.4 Strategic Initiative
                  7.5 LabCorp
                      7.5.1 Company Overview
                      7.5.2 Financial Performance
                      7.5.3 Service Benchmarking
                      7.5.4 Strategic Initiatives
                  7.6 Allergan Plc
                      7.6.1 Company Overview
                      7.6.2 Financial Performance
                      7.6.3 Service Benchmarking
                      7.6.4 Strategic Initiatives
                  7.7 Cadila Healthcare Ltd.
                      7.7.1 Company Overview
                      7.7.2 Financial Performance
                      7.7.3 Service Benchmarking
                      7.7.4 Strategic Initiatives
                  7.8 Eli Lilly
                      7.8.1 Company Overview
                      7.8.2 Financial Performance
                      7.8.3 Service Benchmarking
                      7.8.4 Strategic Initiatives
                  7.9 Novo Nordisk
                      7.9.1 Company Overview
                      7.9.2 Financial Performance
                      7.9.3 Service Benchmarking
                      7.9.4 Strategic Initiatives
                  7.10 Glaxosmith Kline
                      7.10.1 Company Overview
                      7.10.2 Financial Performance
                      7.10.3 Service Benchmarking
                      7.10.4 Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by region, 2018 - 2030 (USD Million)
Table 4 Global Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 5 Global Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 6 North America Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
Table 7 North America Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 8 North America Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 9 U.S. Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 10 U.S. Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 11 Canada Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 12 Canada Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 13 Europe Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
Table 14 Europe Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 15 Europe Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 16 U.K. Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 17 U.K. Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 18 Germany Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 19 Germany Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 20 France Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 21 France Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 22 Italy Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 23 Italy Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 24 Spain Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 25 Spain Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 26 France Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 27 France Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 28 Asia Pacific Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
Table 29 Asia Pacific Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 30 Asia Pacific Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 31 India Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 32 India Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 33 Japan Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 34 Japan Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 35 China Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 36 China Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 37 Australia Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 38 Australia Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 39 South Korea Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 40 South Korea Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 41 Latin America Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
Table 42 Latin America Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 43 Latin America Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 44 Brazil Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 45 Brazil Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 46 Mexico Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 47 Mexico Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 48 Argentina Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 49 Argentina Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 50 Colombia Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 51 Colombia Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 52 MEA Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
Table 53 MEA Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 54 MEA Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 55 South Africa Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 56 South Africa Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 57 South Arabia Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 58 South Arabia Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 59 UAE Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 60 UAE Non-alcoholic Steatohepatitis (NASH) Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Secondary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Non-alcoholic Steatohepatitis (NASH) Clinical Trials market snapshot (2021)
Fig. 9 Non-alcoholic Steatohepatitis (NASH) Clinical Trials market segmentation
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Porter’s five forces analysis
Fig. 14 PESTEL analysis
Fig. 15 Non-alcoholic Steatohepatitis (NASH) Clinical Trials market Phase outlook: Segment dashboard
Fig. 16 Non-alcoholic Steatohepatitis (NASH) Clinical Trials market: Phase movement analysis
Fig. 17 Phase I market, 2018 - 2030 (USD Million)
Fig. 18 Phase II market, 2018 - 2030 (USD Million)
Fig. 19 Phase III market, 2018 - 2030 (USD Million)
Fig. 20 Phase IV market, 2018 - 2030 (USD Million)
Fig. 21 Non-alcoholic Steatohepatitis (NASH) Clinical Trials market Study Design outlook: Segment dashboard
Fig. 22 Non-alcoholic Steatohepatitis (NASH) Clinical Trials market: Study Design movement analysis
Fig. 23 Interventional based Non-alcoholic Steatohepatitis (NASH) Clinical Trials market, 2018 - 2030 (USD Million)
Fig. 24 Observational based Non-alcoholic Steatohepatitis (NASH) Clinical Trials market, 2018 - 2030 (USD Million)
Fig. 25 Expanded Access-based Non-alcoholic Steatohepatitis (NASH) Clinical Trials market, 2018 - 2030 (USD Million)
Fig. 26 Regional market: Key takeaways
Fig. 27 Regional outlook, 2020 & 2028
Fig. 28 North America market, 2018 - 2030 (USD Million)
Fig. 29 U.S. market, 2018 - 2030 (USD Million)
Fig. 30 Canada market, 2018 - 2030 (USD Million)
Fig. 31 Europe market, 2018 - 2030 (USD Million)
Fig. 32 U.K. market, 2018 - 2030 (USD Million)
Fig. 33 Germany market, 2018 - 2030 (USD Million)
Fig. 34 France market, 2018 - 2030 (USD Million)
Fig. 35 Italy market, 2018 - 2030 (USD Million)
Fig. 36 Spain market, 2018 - 2030 (USD Million)
Fig. 37 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 38 Japan market, 2018 - 2030 (USD Million)
Fig. 39 China market, 2018 - 2030 (USD Million)
Fig. 40 India market, 2018 - 2030 (USD Million)
Fig. 41 Australia market, 2018 - 2030 (USD Million)
Fig. 42 SouthKorea market, 2018 - 2030 (USD Million)
Fig. 43 Latin America market, 2018 - 2030 (USD Million)
Fig. 44 Brazil market, 2018 - 2030 (USD Million)
Fig. 45 Mexico market, 2018 - 2030 (USD Million)
Fig. 46 Argentina market, 2018 - 2030 (USD Million)
Fig. 47 Colombia market, 2018 - 2030 (USD Million)
Fig. 48 MEA market, 2018 - 2030 (USD Million)
Fig. 49 South Africa market, 2018 - 2030 (USD Million)
Fig. 50 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 51 UAE market, 2018 - 2030 (USD Million)